U.S. Markets closed

Top Research Reports for Apple, Amgen & United Technologies

Mark Vickery
Top Research Reports for Apple, Amgen & United Technologies

Tuesday, March 26, 2019

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Amgen (AMGN) and United Technologies (UTX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Apple’s shares have gained +9.2% in the past year and have outperformed the broader market with the S&P 500 increasing +5.5% over the same period. The Zacks analyst thinks Apple is likely to be hurt by weak demand for the iPhone, particularly in China and emerging economies.

The company has failed to penetrate rapidly growing but price sensitive markets of Asia, particularly India. It continues to lose share in the smartphone market due to increasing competition from Chinese handset makers. Nevertheless, the Services segment is expected to grow strongly, driven by solid App Store sales, and increasing adoption of Apple Music and Apple Pay.

Apple's endeavors to open up its ecosystem, through partnerships with the likes of Samsung and Amazon, are likely to aid the Services segment. The latest announcement of subscription-based video streaming, news and gaming services is a catalyst. The new credit card, supported by Goldman Sachs and Mastercard, will benefit from Apple Pay’s growing adoption.

(You can read the full research report on Apple here >>>).

Shares of Amgen have declined -4.2% year to date, underperforming the Zacks Biomedical and Genetics industry's increase of +8.1%. The Zacks analyst thinks that while Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, its legacy products face biosimilar and brand competition which will create pressure on the top line in 2019.

Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. The recent price cut will hurt sales going forward. However, Amgen is progressing well with its pipeline and the approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas.

Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some support to the bottom line.

(You can read the full research report on Amgen here >>>).

United Technologies’ shares have lost -10.2% in the past six months, underperforming the Zacks Diversified Operations industry, which has declined -4.6% over the same period. The Zacks analyst thinks strength in commercial and military aftermarket businesses and impressive contribution from last year’s acquisition Rockwell Collins’ sales will likely boost United Technologies' near-term revenues.

Also, improved top line and cost-cutting measures are expected to enhance profitability, going forward. Backed by these positives, the company has given bullish full-year 2019 revenue guidance. The company intends to become more competent on the back of meaningful business acquisitions.

Notably, the Rockwell Collins buyout is likely to boost sales in 2019. Rising costs of sales remain a threat to the company's gross margin. If unchecked, higher costs and operating expenses will prove detrimental to United Technologies' margins and profitability. Moreover, increases in debt level can increase its financial obligations.

(You can read the full research report on United Technologies here >>>).

Other noteworthy reports we are featuring today include Travelers Companies (TRV), Red Hat (RHT) and Xilinx (XLNX).

Is Your Investment Advisor Fumbling Your Financial Future?

See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”

Click to get it free >>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Streaming, News, Gaming to Aid Apple's (AAPL) Services Growth


Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes


High Operating Costs Hurt United Technologies (UTX)


Featured Reports

Strong Deal Win, Expanding Customer Base Aids Red Hat (RHT)

According to the Zacks analyst, Red Hat is benefiting from strong deal win, improving recurring revenues, cross-selling of cloud-based technology and expanding customer base.

Technology, DARTs Aid Interactive Brokers (IBKR), Costs Rise

Per the Zacks analyst, Interactive Brokers' focus on developing of proprietary software have resulted in increase in revenues and daily average revenue trades (DARTs).

Parcel Volumes Buoy ZTO Express (ZTO) Amid Cost Woes

The Zacks analyst likes the growth in parcel volumes. Parcel volumes increased 37.1% in 2018. High operating expenses are, however, a concern.

Acquisitions Buoy C.H. Robinson (CHRW) Amid Debt Woes

The Zacks analyst likes the company's growth-by-acquisition policy. Efforts to reward shareholders are also impressive.

Extended Stay (STAY) Banks on Unit Growth Amid Competition

The Zacks analyst is encouraged by Extended Stay's continual expansion endeavors and the company's pipeline growth in the past year.

Acquisition, Organic Assets Aid Covanta (CVA) Amid Rising Debt

Per the Zacks analyst Covanta's strategic acquisitions and investments to expand its organic operations are assisting growth.

Infinity (INFI) Aims at Developing IPI-549 Amid Competition

Per the Zacks analyst, Infinity is focussed on the develoment of its lead pipeline candidate-IPI-549 despite stiff competition.

New Upgrades

Solid Underwriting, Compelling Portfolio Aid Travelers (TRV)

Per the Zacks analyst, Travelers is set to grow on strong market position, economies of scale, compelling product portfolio, solid underwriting, strategic alliances and effective capital deployment.

Yum! Brands (YUM) Grows on Digital Innovation & Franchising

The Zacks analyst expects Yum! Brands' digital initiatives to drive growth. Further, by refranchising and efficient cost structure, the company is facilitating earnings growth.

Cabot (COG) Thrives on Attractive Marcellus Shale Assets

The Zacks analyst believes that Cabot's large acreage holdings in the fast-growing Marcellus Shale will enable the company to deliver strong natural gas production growth.

New Downgrades

Escalating Expenses & Acute Competition Ail Xilinx (XLNX)

Per the Zacks analyst, Xilinx is hurt by rising operating expenses due to higher employee compensation and the full integration of the DeePhi buyout. Stiff competition from Intel is another concern.

Paychex (PAYX) Continues to Grapple With Higher Expenses

The Zacks analyst is worried about Paychex's rising expenses incurred to fund growth of PEO business and higher compensation-related costs and acquisitions.

Rising Costs Hurt TD Ameritrade's (AMTD) Bottom-line Growth

Per the Zacks analyst, TD Ameritrade's bottom-line remains under pressure due to continued rise in operating expenses due to the company's investments in technology and advice and guidance offerings.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Xilinx, Inc. (XLNX) : Free Stock Analysis Report
 
United Technologies Corporation (UTX) : Free Stock Analysis Report
 
The Travelers Companies, Inc. (TRV) : Free Stock Analysis Report
 
Red Hat, Inc. (RHT) : Free Stock Analysis Report
 
Amgen Inc. (AMGN) : Free Stock Analysis Report
 
Apple Inc. (AAPL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research